Study name (time period) | Population | Group 1 (μg/L) | Group 2 (μg/L) | Group 3 (μg/L) | Group 4 (μg/L) | Group 5 (μg/L) | Weighted mean |
---|---|---|---|---|---|---|---|
INSERM (1999–2001) | Men 20-45y | 1.06 | 1.56 | 3.90 | 7.25 | 14.79 | 7.14 |
KARUPROSTATE (2005–2006) | Men >44y | 0.17 | 0.22 | 0.40 | 0.90 | 7.60 | 2.32 |
Difference : after 2003 - before 2003 | −0.90 | −1.34 | −3.50 | −6.35 | −7.19 | −4.82 | |
HIBISCUS (2003) | Mother 17-45y | 0.32 | 0.62 | 1.70 | 3.05 | 8.05 | 3.43 |
TIMOUN (2004–2007) | Mother 17-45y | 0.18 | nc | 0.29 | 0.65 | 4.17 | 1.37 |
Difference : after 2003 - before 2003 | −0.15 | −0.40 | −1.30 | −2.15 | −0.45 | −1.11 | |
HIBISCUS (2003) | Newborn | 0.39 | nc | 0.55 | 0.95 | 2.11 | 1.00 |
TIMOUN (2004–2007) | Newborn | 0.19 | nc | nc | 0.24 | 2.62 | 0.81 |
Difference : after 2003 - before 2003 | −0.21 |  |  | −0.71 | +0.51 | −019 |